Dare Bioscience, Inc. (DARE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Dare Bioscience, Inc. reported revenue of $1.03M, up 10429.4% from the prior year. The company ran a net loss, with a net margin of -1300.7%. It held $32.47M in total assets against $29.63M in total liabilities.
Key ratios (FY2025)
-1315.5%
Operating margin
-1300.7%
Net margin
-471.4%
Return on equity
+10429.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03M | $9.8K | $2.81M | $10.00M | $0 | — | — | — | — | — |
| Cost of Revenue | $295.8K | $0 | — | — | — | — | — | — | — | — |
| Operating Income | -$13.55M | -$23.45M | -$30.94M | -$31.39M | -$39.07M | -$27.40M | -$14.34M | -$16.88M | -$11.18M | -$630.6K |
| Net Income | -$13.40M | -$4.05M | -$30.16M | -$30.95M | -$38.70M | -$27.40M | -$14.26M | -$16.74M | -$11.50M | -$672.7K |
| EPS (Diluted) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.91 | — | — | — | — |
| Total Assets | $32.47M | $22.10M | $21.28M | $43.83M | $55.81M | $7.55M | $7.44M | $7.83M | $14.26M | $44.6K |
| Total Liabilities | $29.63M | $28.11M | $26.33M | $32.71M | $17.05M | $8.70M | $7.00M | $1.10M | $967.0K | $755.2K |
| Shareholders' Equity | $2.84M | -$6.01M | -$5.05M | $11.11M | $38.75M | -$1.15M | $440.8K | $6.73M | $13.29M | -$710.6K |
| Cash & Equivalents | $24.71M | $15.70M | $10.48M | $34.67M | $51.67M | $4.67M | $4.78M | $6.81M | $7.56M | $44.6K |
| Operating Cash Flow | -$9.90M | $5.40M | -$38.90M | -$18.10M | -$28.80M | -$25.20M | -$13.30M | -$10.30M | -$2.54M | -$372.3K |
| Capital Expenditures | $385.3K | $573.0K | $629.4K | $63.1K | $14.5K | $17.6K | $0 | $11.8K | $0 | $535.0K |
| Shares Outstanding | 14.50M | 8.70M | 8.33M | 84.83M | 83.94M | 41.60M | 19.68M | 11.42M | 6.05M | 910.0K |